Clinical trials informing this study consistently showed no statistically significant improvement in OS for afatinib compared with platinum-based chemotherapy for EGFR mutation-positive NSCLC, although significant improvements in PFS were demonstrated. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.